PORTOLA PHARMACEUTICALS
Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include P... RT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.
PORTOLA PHARMACEUTICALS
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2003-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.portola.com
Total Employee:
51+
Status:
Closed
Contact:
650.246.7000
Email Addresses:
[email protected]
Total Funding:
1.31 B USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail ReCAPTCHA Cloudflare JS CDN JS Amazon Route 53 Pound Sterling Japanese Yen
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - Portola Pharmaceuticals
HealthCare Royalty Partners
HealthCare Royalty Partners investment in Post-IPO Debt - Portola Pharmaceuticals
Eastern Capital
Eastern Capital investment in Series D - Portola Pharmaceuticals
Temasek Holdings
Temasek Holdings investment in Series D - Portola Pharmaceuticals
Biogen Idec
Biogen Idec investment in Corporate Round - Portola Pharmaceuticals
AllianceBernstein
AllianceBernstein investment in Series C - Portola Pharmaceuticals
Adage Capital Management
Adage Capital Management investment in Series C - Portola Pharmaceuticals
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series C - Portola Pharmaceuticals
Pac-Link
Pac-Link investment in Series C - Portola Pharmaceuticals
Prospect Venture Partners
Prospect Venture Partners investment in Series C - Portola Pharmaceuticals
Key Employee Changes
Date | New article |
---|---|
2020-02-04 | Portola Picks Adamas Pharmaโs Patni for Chief Medical Officer Role |
Official Site Inspections
http://www.portola.com Semrush global rank: 418.85 K Semrush visits lastest month: 129.78 K
- Host name: server-3-171-76-7.iad89.r.cloudfront.net
- IP address: 3.171.76.7
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109